Replies to post #1034 on RedHill Biopharma Ltd (RDHL)

[midastouch017]

RedHill nabs U.S. rights to GERD med Esomeprazole Strontium DR Capsules; shares up 4% premarket

Aug. 17, 2017 7:37 AM ET|By: Douglas W. House, SA News Editor
RedHill Biopharma (NASDAQ:RDHL) inks a commercialization agreement with ParaPRO LLC securing the exclusive rights to promote Esomeprazole Strontium Delayed-Release (DR) Capsules to gastroenterologists in certain U.S. territories for a initial term of three years. The product is FDA-approved to treat gastroesophageal reflux disease (GERD) and other GI conditions.

Under the terms of the agreement, RedHill will not obligated for any upfront or milestone payments, but will share revenues with ParaPRO per an agreed-upon split.

U.S. launch will commence in the coming weeks.

Shares are up 4% premarket but only on 900 shares.

[H2R]

Thanks Midastouch,

They continue to execute on their plans, keep cash in the coffers, prepare for this GI product, a deep pipeline with Ph III trials including Efficacy and Safety of Anti-MAP Therapy in Adult Crohn's Disease (MAPUS)and an Estimated Completion date of Sept '17!

This continues to looking good.